var data={"title":"Micafungin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Micafungin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6578?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">see &quot;Micafungin: Drug information&quot;</a> and <a href=\"topic.htm?path=micafungin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Micafungin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196257\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Mycamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5505640\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mycamine</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1761796\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Echinocandin</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11443889\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fungal infections, susceptible:</b> Limited data available; dosing based on several pharmacokinetic studies in preterm infants (Benjamin 2010; Caudle 2012; Heresi 2006; Hope 2010; Smith 2009): IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&lt;1,000 g: 10 mg/kg/day once daily; doses as high as 15 mg/kg/day have been used; dosages at the higher end of the dosing range should be considered for treating CNS infections due to poor micafungin CNS penetration (Caudle 2012) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&ge;1,000 g: 7 to 10 mg/kg/day once daily; HIV-exposed/-positive neonates may require up to 10 to 12 mg/kg/day once daily (DHHS [pediatric] 2013)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1761806\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">see &quot;Micafungin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Aspergillosis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Treatment; invasive disease</i>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infants &ge;4 months and Children; independent of HIV status: IV: 1.5 to 3 mg/kg/day once daily; titration to a higher dose may be necessary for lack of clinical response or persistent positive cultures; reported usual maximum dose range: 4 to 8.6 mg/kg/day; in infants, initial doses at the higher end of the dosage range may be necessary due to pharmacokinetic differences (Denning 2006, Emiroglu 2011; Flynn 2006; Kobayashi 2007; Singer 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HIV-exposed/-positive: IV: 1.5 mg/kg/day; increase if clinically indicated; maximum daily dose: 150 mg/<b>day</b>; dosing based on a noncomparative study of all ages, an abstract describing a study in pediatric patients 3 months to 16 years and single case report of a 13-year old who received 1.5 mg/kg/day for invasive aspergillosis (Denning 2006; Emiroglu 2011; Flynn 2006; Singer 2003).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-exposed/-positive: IV: 100 to 150 mg once daily (DHHS [adult] 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Prophylaxis in hematopoietic stem cell transplantation (HSCT):</i> Limited data available: Infants &ge;4 months, Children, and Adolescents: IV: 1 to 3 mg/kg daily; maximum dose: 50 mg (Kusuki 2009; Tomblyn 2009; van Burik 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Acute disseminated infection, peritonitis, and abscesses; treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HIV-exposed/-positive: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;4 months: Limited data available: IV: 2 mg/kg/day once daily; may increase higher doses (4 to 10 mg/kg/day) if no improvement in condition, or persistent positive cultures; reported range: 2 to 10 mg/kg/day (Benjamin 2010; Hope 2010; Myacin prescribing information [European Medicines Agency] 2013; Queiroz-Telles 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;4 months, Children, and Adolescents: IV: 2 mg/kg once daily; maximum dose: 100 mg/dose </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-exposed/-positive (DHHS [pediatric] 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;4 months (critically ill): IV: 5 to 7 mg/kg/day once daily; treatment duration variable, continue treatment for 2 weeks following last positive blood culture </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;4 months and weighing &lt;15 kg: IV: 5 to 7 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 8 years and &le;40 kg: IV: 3 to 4 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;40 kg: IV: 2 to 3 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;40 kg: IV: 100 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Esophageal candidiasis, treatment:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Non-HIV-exposed/-positive: Infants &ge;4 months, Children, and Adolescents: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&le;30 kg: IV: 3 mg/kg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">&gt;30 kg: IV: 2.5 mg/kg once daily; maximum dose: 150 mg/dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">HIV-exposed/-positive (DHHS [adult/pediatric] 2013): </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &lt;4 months: IV: 5 to 7 mg/kg/day once daily; treatment duration: &ge;3 weeks and for at least 2 weeks following symptom resolution  </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;4 months and weighing &lt;15 kg: IV: 5 to 7 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to 8 years and &le;40 kg: IV: 3 to 4 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;9 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&le;40 kg: IV: 2 to 3 mg/kg once daily</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&gt;40 kg: IV: 100 mg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&lt;40 kg: IV: 2 to 3 mg/kg once daily </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">&ge;40 kg: IV: 150 mg once daily; treatment duration: 14 to 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Prophylaxis in hematopoietic stem cell transplantation:</i> Infants &ge;4 months, Children, and Adolescents: IV: 1 mg/kg daily; maximum dose: 50 mg; doses as high as 3 mg/kg/day have been used in trials (Kusuki 2009; van Burik 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidemia, acute disseminated candidiasis, and <i>Candida</i> peritonitis and abscesses:</b> IV: 100 mg daily; mean duration of therapy (from clinical trials): 15 days (range: 10 to 47 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Esophageal candidiasis:</b> IV: 150 mg daily; mean duration of therapy (from clinical trials): 15 days (range: 10 to 30 days)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Prophylaxis of <i>Candida</i> infection in hematopoietic stem cell transplantation:</b> IV: 50 mg daily </p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> Adults: No adjustment required; not dialyzable, supplemental dosing is not required following hemodialysis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> Adults: No adjustment required. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196241\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mycamine: 50 mg (1 ea); 100 mg (1 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Mycamine: 50 mg (1 ea); 100 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3884043\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1761807\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: In pediatric patients, final concentrations  &gt;1.5 mg/mL should be administered via a central line to minimize risk of infusion reactions. Prior to administration, flush line with NS. Infuse over 1 hour; more rapid infusions may result in a higher incidence of histamine-mediated reactions. Do not coinfuse with other medications since precipitation may occur. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196252\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 25&deg;C (77&deg;F); excursions permitted to 15&deg;C  to 30&deg;C (59&deg;F to 86&deg;F). Reconstituted and diluted solutions in D5W or NS are stable for 24 hours at room temperature. Protect infusion solution from light (it is not necessary to protect the drip chamber or tubing from light).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1761797\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of patients with esophageal candidiasis; treatment of candidemia, acute disseminated candidiasis, <i>Candida</i> peritonitis and abscess; prophylaxis of <i>Candida</i> infections in patients undergoing hematopoietic stem cell transplant (All indications: FDA approved in ages &ge;4 months and adults); has been used for treatment of invasive <i>Aspergillosis</i>; micafungin is ineffective against cryptococcosis, fusariosis, and zygomycosis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196271\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Candidiasis treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Atrial fibrillation (adults), phlebitis, tachycardia (pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Abnormal aspartate transaminase, hyperkalemia (adults), hypernatremia (adults), hypoglycemia (adults)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (pediatric), abdominal pain (pediatric), diarrhea, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (pediatric), neutropenia (pediatric), thrombocytopenia (pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (pediatric), hyperbilirubinemia (pediatric), increased serum alkaline phosphatase</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Abnormal hepatic function tests (more common in pediatrics), renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Candidiasis prophylaxis in hematopoietic stem cell transplantation</b>\n      <b>:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrest, myocardial infarction, pericardial effusion, tachycardia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Anxiety, brain disease, delirium, headache (adults), insomnia (adults), intracranial hemorrhage, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Pruritus (pediatric), skin rash, urticaria (more common in pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Abnormal alanine aminotransferase (pediatric; increased)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distention (pediatric), abdominal pain, diarrhea (more common in adults), nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Decreased urine output (pediatric), hematuria (pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (pediatric), blood coagulation disorder, febrile neutropenia (pediatric), neutropenia, pancytopenia, thrombocytopenia, thrombotic thrombocytopenic purpura</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (pediatric), hepatic failure, hepatic injury, hepatomegaly, hyperbilirubinemia (pediatric), jaundice</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Infusion site reaction, venous thrombosis at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Epistaxis (pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (pediatric), infusion-related reaction (pediatric)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening (all indications): Disseminated intravascular coagulation, hepatic disease, renal insufficiency, shock, Stevens-Johnson syndrome, toxic epidermal necrolysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196246\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to micafungin, other echinocandins, or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196233\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hemolytic anemia/hemoglobinuria: Hemolytic anemia and hemoglobinuria have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: New-onset or worsening hepatic impairment, including hepatitis and hepatic failure, has been reported. Monitor closely and evaluate appropriateness of continued use in patients who develop abnormal liver function tests during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hypersensitivity reactions: Severe anaphylactic reactions, including shock, have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Increased BUN, serum creatinine, renal dysfunction, and/or acute renal failure has been reported; use with caution in patients that develop worsening renal function during treatment; monitor closely. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F747105\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F747104\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12713&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sirolimus: Micafungin may increase the serum concentration of Sirolimus. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196238\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196248\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. There are no adequate and well-controlled studies in pregnant women. Use only if benefit outweighs risk.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1761808\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic liver function tests, renal function tests, CBC with differential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196232\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Concentration-dependent inhibition of 1,3-beta-D-glucan synthase resulting in reduced formation of 1,3-beta-D-glucan, an essential polysaccharide comprising 30% to 60% of <i>Candida</i> cell walls (absent in mammalian cells); decreased glucan content leads to osmotic instability and cellular lysis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F196245\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Distributes into lung, liver, and spleen; minimally to CNS and eyes (Caudle 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm infants (ELBW): Reported data highly variable; possibly dependent on GA/weight, and PNA: V<sub>dss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 0-1 day: 0.76 L/kg (Kawada 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 4 days: 1.52 L/kg (Smith 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &gt;3 weeks: 0.43 L/kg (range: 0.28 to 0.66 L/kg) (Heresi 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 2 to 8 years: V<sub>dss</sub>: 0.35 &plusmn; 0.18 L/kg (Seibel 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children and Adolescents 9 to 17 years: V<sub>dss</sub>: 0.28 &plusmn; 0.09 L/kg (Seibel 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: V<sub>d</sub>: 0.39 &plusmn; 0.11 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Neonates: 96.7% (Yanni 2011); Adults: &gt;99% to albumin</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic to M-1, catechol form by arylsulfatase; further metabolized to M-2, methoxy form by catechol-O-methyltransferase; hydroxylation to M-5 by CYP3A </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm infants: PNA &lt;1 week: 6.7 hours (Kawada 2009); PNA &gt;3 weeks: Mean 8.3 hours (range: 5.6 to 11 hours) (Heresi 2006)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 months to 16 years: &le;30 kg: 12.5 &plusmn; 4.6 hours; &gt;30 kg: 13.6 &plusmn; 8.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Healthy Adults: 11 to 21 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults receiving bone marrow or peripheral stem-cell transplantation: 10.7 to 13.5 hours (Carver 2004) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Primarily feces (71%); urine (&lt;1%, unchanged [Herbert 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Preterm infants: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 0 to 1 day: 1.48 mL/minute/kg (Kawada 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA 4 days: 0.58 mL/minute (Smith 2009) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">PNA &gt;3 weeks: 0.64 mL/minute (Heresi 2006) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Children 4 months to 16 years: &le;30 kg: 0.328 mL/minute/kg; &gt;30 kg: 0.241 mL/minute/kg </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Adults: ~0.3 mL/minute/kg </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323399\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Mycamine Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (1): $112.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">100 mg (1): $224.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038681\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Funguard (JP);</li>\n      <li>Micamin (RU);</li>\n      <li>Mikamin (UA);</li>\n      <li>Mycamiine (SK);</li>\n      <li>Mycamine (AT, AU, BB, BR, CH, CN, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HN, HR, ID, IE, IL, IN, IS, IT, JO, KR, KW, LB, LT, LV, MT, MY, NL, NO, PH, PL, PT, QA, RO, SA, SE, SG, SI, TH, TR, TW)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ashouri N, Singh J, Arrieta A. Micafungin in pediatrics:  when one size does not fit all. <i>Expert Opin Drug Metab Toxicol</i>. 2008;4(4):463-469.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/18433348/pubmed\" target=\"_blank\" id=\"18433348\">18433348</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Benjamin DK Jr, Smith PB, Arrieta A, et al, &quot;Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants,&quot; <i>Clin Pharmacol Ther</i>, 2010, 87(1):93-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19890251/pubmed\" target=\"_blank\" id=\"19890251\">19890251</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Carver PL. Micafungin. <i>Ann Pharmacother</i>. 2004;38(10):1707-1721.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15340133/pubmed\" target=\"_blank\" id=\"15340133\">15340133</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Caudle KE, Inger AG, Butler DR, et.al. Echinocandin use in the neonatal intensive care unit. <i>Ann Pharmacother</i>. 2012;46:108-116.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/22190252/pubmed\" target=\"_blank\" id=\"22190252\">22190252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Denning DW, Marr KA, Lau WM, et al, &quot;Micafungin (FK463), Alone or in Combination With Other Systemic Antifungal Agents, for the Treatment of Acute Invasive Aspergillosis,&quot; <i>J Infect</i>, 2006, 53(5):337-49.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16678903/pubmed\" target=\"_blank\" id=\"16678903\">16678903</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at: <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DHHS Panel on Opportunistic Infections (OI) in HIV-Infected Adults and Adolescents, &quot;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), and the HIV Medicine Association (HIVMA) of the Infectious Diseases Society of America (IDSA),&quot; May 7, 2013. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Emiroglu M. Micafungin use in children. <i>Expert Reviews Anti-infective Therapy</i>. 2011;9(9):821-834.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21905789/pubmed\" target=\"_blank\" id=\"21905789\">21905789</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Flynn PM, Seibel N, Arrieta A, et al, &quot;Treatment of Invasive Aspergillosis in Pediatric Patients With Micafungin Alone or in Combination with Other Systemic Antifungal Agents,&quot; Program and abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, 2006, September 27-30 (abstract M-891).</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Herbert MF, Smith HE, Marbury TC, et al. Pharmacokinetics of micafungin in healthy volunteers, volunteers with moderate liver disease, and volunteers with renal dysfunction. <i>J Clin Pharmacol</i>. 2005;45(10):1145-1152.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16172179/pubmed\" target=\"_blank\" id=\"16172179\">16172179</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heresi GP, Gerstmann DR, Reed MD, et al, &quot;The Pharmacokinetics and Safety of Micafungin, a Novel Echinocandin, in Premature Infants,&quot; <i>Pediatr Infect Dis J</i>, 2006, 25(12):1110-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17133155/pubmed\" target=\"_blank\" id=\"17133155\">17133155</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hope WW, Smith PB, Arrieta A, et al. Population pharmacokinetics of micafungin in neonates and young infants. <i>Antimicrob Agents Chemother</i>. 2010;54(6):2633-2637. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/20308367/pubmed\" target=\"_blank\" id=\"20308367\">20308367</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kawada M, Fukuoka N, Kondo M, et al, &quot;Pharmacokinetics of Prophylactic Micafungin in Very-Low-Birth-Weight Infants,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(9):840-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19636279/pubmed\" target=\"_blank\" id=\"19636279\">19636279</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kobayashi S, Murayama S, Tatsuzawa O, et al, &quot;X-Linked Severe Combined Immunodeficiency (X-SCID) With High Blood Levels of Immunoglobulins and <i>Aspergillus</i> Pneumonia Successfully Treated With Micafangin Followed by Unrelated Cord Blood Stem Cell Transplantation,&quot; <i>Eur J Pediatr</i>, 2007, 166(3):207-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16915374/pubmed\" target=\"_blank\" id=\"16915374\">16915374</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kusuki S, Hashii Y, Yoshida H, et al, &quot;Antifungal Prophylaxis With Micafungin in Patients Treated for Childhood Cancer,&quot; <i>Pediatr Blood Cancer</i>, 2009, 53(4):605-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19533659/pubmed\" target=\"_blank\" id=\"19533659\">19533659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes D, et al, &quot;Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2009, 48(5):503-35. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19191635/pubmed\" target=\"_blank\" id=\"19191635\">19191635</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Queiroz-Telles F, Berezin E, Leverger G, et al, &quot;Micafungin Versus Liposomal Amphotericin B for Pediatric Patients With Invasive Candidiasis: Substudy of a Randomized Double-Blind Trial,&quot; <i>Pediatr Infect Dis J</i>, 2008, 27(9):820-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/18679151/pubmed\" target=\"_blank\" id=\"18679151\">18679151</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos RP, S&aacute;nchez PJ, Mejias A, et al, &quot;Successful Medical Treatment of Cutaneous <i>Aspergillosis</i> in a Premature Infant Using Liposomal Amphotericin B, Voriconazole and Micafungin,&quot; <i>Pediatr Infect Dis J</i>, 2007,  26(4):364-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/17414408/pubmed\" target=\"_blank\" id=\"17414408\">17414408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Seibel NL, Schwartz C, Arrieta A, et al, &quot;Safety, Tolerability, and Pharmacokinetics of Micafungin (FK463) in Febrile Neutropenic Pediatric Patients,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(8):3317-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/16048942/pubmed\" target=\"_blank\" id=\"16048942\">16048942</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Singer MS, Seibel NL, Vezina G, et al, &quot;Successful Treatment of Invasive <i>Aspergillosis</i> in Two Patients With Acute Myelogenous Leukemia,&quot; <i>J Pediatr Hematol Oncol</i>, 2003, 25(3):252-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/12621247/pubmed\" target=\"_blank\" id=\"12621247\">12621247</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smith PB, Walsh TJ, Hope W, et al, &quot;Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates,&quot; <i>Pediatr Infect Dis J</i>, 2009, 28(5):412-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19319022/pubmed\" target=\"_blank\" id=\"19319022\">19319022</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tomblyn M, Chiller T, Einsele H, et.al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. <i>Biol Blood Marrow Transplant</i>. 2009;15:1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van Burik JA, Ratanatharathorn V, Stepan DE, et al, &quot;Micafungin Versus Fluconazole for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Hematopoietic Stem Cell Transplantation,&quot; <i>Clin Infect Dis</i>, 2004, 39(10):1407-16.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/15546073 /pubmed\" target=\"_blank\" id=\"15546073 \">15546073 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yanni, SB, Smith PB, Benjamin DK, et.al. Higher clearance of micafungin in neonates compared to adults: rose of age-dependent micafungin serum binding. <i>Biopharm Drug Dispos</i>. 2011;32(4):222-232.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/micafungin-pediatric-drug-information/abstract-text/21449041/pubmed\" target=\"_blank\" id=\"21449041\">21449041</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12713 Version 93.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F196257\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F5505640\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1761796\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11443889\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1761806\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F196241\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F3884043\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1761807\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F196252\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1761797\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F196271\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F196246\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F196233\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F747105\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F747104\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F196238\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F196248\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1761808\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F196232\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F196245\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323399\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038681\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12713|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=micafungin-drug-information\" class=\"drug drug_general\">Micafungin: Drug information</a></li><li><a href=\"topic.htm?path=micafungin-patient-drug-information\" class=\"drug drug_patient\">Micafungin: Patient drug information</a></li></ul></div></div>","javascript":null}